Compare NCSM & NTHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NCSM | NTHI |
|---|---|---|
| Founded | 2006 | 2008 |
| Country | United States | United States |
| Employees | N/A | 5 |
| Industry | Oilfield Services/Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 112.0M | 114.6M |
| IPO Year | 2017 | N/A |
| Metric | NCSM | NTHI |
|---|---|---|
| Price | $47.00 | $3.49 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | 9.5K | ★ 59.0K |
| Earning Date | 04-29-2026 | 05-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 239.22 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $142,471,000.00 | N/A |
| Revenue This Year | $5.57 | N/A |
| Revenue Next Year | $4.81 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $29.48 | $3.01 |
| 52 Week High | $87.36 | $12.99 |
| Indicator | NCSM | NTHI |
|---|---|---|
| Relative Strength Index (RSI) | 45.09 | 38.66 |
| Support Level | $42.43 | $3.01 |
| Resistance Level | $46.14 | $4.59 |
| Average True Range (ATR) | 1.61 | 0.38 |
| MACD | 0.20 | 0.02 |
| Stochastic Oscillator | 26.04 | 37.83 |
NCS Multistage Holdings Inc is a provider of engineered products and support services that facilitate the optimization of oil and natural gas well construction, well completion, and field development strategies. The company provides its products and services to E&P companies for use in onshore and offshore wells, predominantly those drilled with horizontal laterals in unconventional and conventional oil and natural gas formations. It also provides tracer diagnostics services and sells products for well construction including casing buoyancy systems, liner hanger systems and toe initiation sleeves, along with certain complementary products from third parties. The company operates in the United States, Canada and other countries, with the majority of its revenue generated from Canada.
NeOnc Technologies Holdings Inc. is a clinical-stage biopharmaceutical company focused on developing novel molecular technologies for the targeted delivery of therapeutics to treat central nervous system diseases. The company is developing drug delivery methods and drug candidates for intracranial malignancies such as gliomas, glioblastoma, and meningioma. Its lead product candidates include NEO100, an intranasal drug delivery therapy for brain cancer patients, and NEO212, an oral chemical conjugate designed to enhance treatment for glioblastoma.